News coverage about Cellect Biotechnology (NASDAQ:APOP) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellect Biotechnology earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3401913675044 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
APOP has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $14.00 price target (up previously from $12.00) on shares of Cellect Biotechnology in a research note on Monday, September 25th. ValuEngine downgraded Cellect Biotechnology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Cellect Biotechnology (NASDAQ:APOP) opened at $7.80 on Monday. Cellect Biotechnology has a 1 year low of $2.30 and a 1 year high of $13.50.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.